<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146237">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196819</url>
  </required_header>
  <id_info>
    <org_study_id>Target I</org_study_id>
    <nct_id>NCT01196819</nct_id>
  </id_info>
  <brief_title>Randomized MicroPort's Firehawk DES Versus Xience V</brief_title>
  <official_title>A Prospective Multicenter Randomized Trial Assessing the Safety and Effectiveness of FIREHAWK BiodeGradable Polymer TArget Release Rapamycin-Eluting STent vs. XIENCE V Everolimus-Eluting Stent for the Treatment of Coronary Artery Disease: TARGET I Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai MicroPort Medical (Group) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai MicroPort Medical (Group) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized study is to evaluate new generation of MicroPort's DES of its
      safety, efficacy and delivery system in treating CAD.

      The end point is to observe in-stent late lumen loss after 9 months of the stent
      implantation. The second end point is to study in-stent percent diameter stenosis.

      This study is based on non-inferior assumption (vs. Xience V DES), requiring both end points
      reach statistical significance.

      Prespecified OCT follow-up is planned at 3-Year after index PCI at 3 chosen hospitals.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>9 months in-stent late lumen loss</measure>
    <time_frame>9 months</time_frame>
    <description>To observe in-stent late lumen loss after 9 months of stent implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>9 months in-stent percent diameter stenosis</measure>
    <time_frame>9 months</time_frame>
    <description>Device, lesion, &amp; clinical success rates In-stent p-edge, d-edge &amp; in-segment BRR, in-segment LLL, in-stent and in-segment percent diameter stenosis, at 9-month, respectively
Device oriented composite of cardiac death, target vessel MI, or ischemia-driven TLR (TLF) at 1-, 6-, 12-month, and annually up to 5 yrs
Patient oriented composite of all cause death, all MI, or any revascularization at 1-, 6-, 12-month, and annually up to 5 yrs
Definite and probable stent thrombosis according to ARC
Proportion of side branch slow flow and occlusion after stent implantation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pre-specified OCT Endpoints</measure>
    <time_frame>3 years after index PCI</time_frame>
    <description>Major Endpoint:
In-stent volumetric obstruction (%) at 3 years
Secondary Endpoints:
Mean / minimal stent diameter / area / volume at 3 years
Mean / minimal lumen diameter / area / volume at 3 years
Mean / maximal thickness of the strut coverage at 3 years
Proportion of covered struts at 3 years
Incomplete stent apposition at 3 years
Incomplete stent apposition (ISA) &gt;2 mm2
Thrombus &gt; 300 microns2
Late lumen loss at 3 years
Binary restenosis rates at 3 years</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">510</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Xience V DES as comparative arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use Xience V DES as control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MicroPort Firehawk DES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use MicroPort's new generation of Firehawk drug eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DES implantation</intervention_name>
    <description>Implant DES for CAD cases</description>
    <arm_group_label>Xience V DES as comparative arm</arm_group_label>
    <arm_group_label>MicroPort Firehawk DES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75, male or women who are not pregnant

          -  Evidence of non-symptomatic ischemia, stable or non-stable angina or past heart
             attack cases

          -  Target lesion is primary, single artery and single lesion of coronary artery

          -  Target lesion vessel length ≤24mm, diameter 2.25mm－4.0mm

          -  Lesion diameter stenosis ≥70%

          -  Candidates understand the study, willing to sign Consent of Agreement and to willing
             to accept follow-up For long lesion group, at least one target lesion length
             ≥28mm，diameter 2.5mm－4.0mm, and one lesion needs to implant 33mm 0r 38mm long stent

        Exclusion Criteria:

          -  Acute heart attack within one week

          -  Chronic complete stenosis (TIMI 0), left main lesion, three branches need to treat,
             branch vessel diameter ≤2.5mm and bypass lesion

          -  Calcified lesion failed in pre-dilation and twisted lesion

          -  In-stent restenosis

          -  Stent implanted within one year

          -  Severe heart failure (NYHA above III) or left ventricle EF &lt;40%

          -  Renal function damage, blood creatinine &gt;2.0mg/dl

          -  Bleeding risk; allergic to drugs and agents used in procedure/treatment

          -  Life expectation &lt; 12 months

          -  No compliances to the protocol

          -  Heart implantation cases

        Pre-specified OCT inclusion/exclusion criteria:

          -  Patients underwent 9-month angio F/U

          -  No binary restenosis at 9-month

          -  LLL between -0.01~0.2mm

          -  No mix-implanted stent

          -  No more than one bail-out stent

          -  No TLR occurred at 3 years after PCI

          -  The target vessel able to deliver the OCT catheter
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Runlin Gao, Pro &amp; MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital, Beijing, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>September 6, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
